Hepatocellular CarcinomaPhase 1NCT06326502
A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma
A Phase 1 study testing ETN101 in people with Hepatocellular Carcinoma and Advanced Hepatocellular Carcinoma, run by Etnova Therapeutics Corp. at 2 sites in South Korea.
Trial summary
ETN101 is a multiple tyrosine kinase inhibitor (mTKI) targeting fms-like tyrosine kinase 3 (FLT3), receptor tyrosine kinase (KIT), vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor receptor beta. Read more about this study
- Who is it for?
- Ages 19 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Liver Cancer
- What is being tested?
- ETN101
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 2 sitesSouth Korea
- Study dates
- 7 Feb 2024to 7 Jun 2027
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male and female adult at the age of ≥ 19 years old
- Patients with radiologically or histologically, and/or cytologically confirmed advanced HCC who have confirmed disease progression on standard therapies known to have clinical benefit or for whom there is no currently available standard therapy due to intolerance or incompatibility.
- Subject with Barcelona Clinic Liver Cancer (BCLC) stage B or C; Subject with Stage B must have had progressive disease (PD) after radical resection, liver transplant, embolization, or cauterization or must be ineligible for such treatment.
- Subject with Child-Pugh score A (5-6)
- Subject who has at least one measurable target lesion based on modified RECIST (mRECIST) which was not previously treated with local therapy. A lesion previously treated with local therapy may be selected as a target lesion if an increase of ≥20% in size is confirmed after treatment.
- Subject with Eastern Cooperative Oncology Group (ECOG) status performance 0-1.
Show all 18Show fewer
- Subject with ≥ 12 weeks of life expectancy
- Subject who meets the following criteria for laboratory tests (Subject must not have been treated with granulocyte colony-stimulating factor (G-CSF) or blood transfusions within 14 days prior to the laboratory tests.):
- Hematology
- Absolute neutrophil count(ANC) ≥1,500/mm3
- Platelet count ≥60,000/mm3
- Hemoglobin(Hb) ≥8.5 g/dL
- Kidney function: Serum creatinine ≤1.5 × upper limit of normal(ULN)
- Liver function
- Aspartate aminotransferase(AST) and alanine aminotransferase(ALT) ≤5 × ULN
- Total bilirubin ≤2.0 × ULN (≤3.0 × ULN for Gilbert's disease)
- Blood coagulation function: Prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN
- Subject who voluntarily agrees to participate in the study and signs the informed consent form (ICF) after being fully informed of the study
Who cannot join
- Individual with severe drug sensitivity or sensitivity reactions to IP and any of its components or drugs in similar classes
- Individual with a confirmed disease which makes oral drug administration difficult or which affects the absorption of orally administered drugs (celiac disease, Crohn's disease, or enterectomy affecting absorption, etc.)
- Individual with any of the following past medical history or surgical/procedure history:
- History of other primary cancer within 3 years from screening (However, individuals who had skin basal cell carcinoma/squamous cell carcinoma, local prostate cancer, papillary thyroid cancer, or cervical intraepithelial neoplasia within 3 years may participate in the study if it is confirmed by the investigator to have been cured following successful treatment.)
- Hepatic radiation, chemoembolization, or radiofrequency ablation within 4 weeks prior to IP administration
- Major surgery within 4 weeks or minor surgery within 2 weeks prior to IP administration
Show all 33Show fewer
- Clinically significant arrhythmia, acute myocardial infarction, unstable angina pectoris, or New York Heart Association (NYHA) Ⅲ or Ⅳ heart failure within 6 months prior to IP administration
- Severe cerebrovascular disease within 6 months prior to IP administration
- Pulmonary thrombosis, deep vein thrombosis, or bronchial asthma or obstructive pulmonary disease that is considered ineligible for study participation, or other life-threatening severe pulmonary disease (e.g., acute respiratory distress syndrome, lung failure) within 6 months prior to IP administration
- Individual with any of the following diseases:
- Clinically significantly symptomatic or uncontrolled central nervous system or brain metastasis (However, individuals who have been stable for ≥ 4 weeks based on repeated imaging and clinical observations, as confirmed by clinical and imaging tests during the screening period, may participate in the study.)
- Clinically significant electrocardiogram (ECG) abnormalities based on the judgment of the investigator
- Uncontrolled hypertension (systolic blood pressure [BP] >140 mmHg or diastolic BP >90 mmHg)
- Grade ≥ 3 active infectious disease requiring treatment. However, individuals with hepatitis B and hepatitis C may be enrolled if replication activity is undetectable (HBV DNA below the limit of detection) and antiviral treatment against hepatitis C is not required, respectively.
- Active autoimmune disease requiring systemic treatment
- Known human immunodeficiency virus (HIV) infection
- Symptomatic ascites or pleural effusion (However, patients who are treated and clinically stabilized may be enrolled.)
- Grade ≥ 3(≥3.5 g/24 h) proteinuria
- Any disease that may affect the interpretation of study results based on the judgment of the investigator
- Individuals who have any of the following history of medication or treatment:
- Anticancer therapy [chemotherapy, hormone therapy, targeted therapy, or radiotherapy, etc.] within 4 weeks prior to IP administration
- Live attenuated vaccines within 4 weeks prior to IP administration
- Strong CYP1A2 inhibitors within 2 weeks prior to IP administration
- Prior allogeneic bone marrow or solid organ transplantation
- Pregnant or lactating woman, or man or woman of childbearing potential who is unwilling to practice abstinence or to use adequate methods of contraception* from after study enrollment to at least 6 months (in female subjects) or 3 months (in male subjects) after the last dose of IP
- Adequate methods of contraception
- Hormonal contraception (subdermal contraceptive implants, injections, oral contraceptives)
- Insertion of intrauterine device or intrauterine system
- Subject's or spouse (partner)'s surgical sterilization (vasectomy, tubal ligation, etc.)
- Individual with prior chemotherapy related toxicity not recovered to Grade ≤ 1 or baseline level (with the exception of alopecia)
- Individual who is unable to undergo contrast-enhanced CT or MRI
- Individual who was treated with another IP or investigational device within 4 weeks prior to IP administration in the present study
- Patient who is ineligible or unable to participate in the study for other reasons based on the judgment of the investigator
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea2 sites, 2 recruiting
- Recruiting
Seoul National University Hospital
Seoul, 03080
- Recruiting
Severance Hospital
Seoul, 03722
About this study
Official title: An Open-label, Multi-center, Dose-escalation Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ETN101 in Patients With Advanced Hepatocellular Carcinoma
ETN101 is a multiple tyrosine kinase inhibitor (mTKI) targeting fms-like tyrosine kinase 3 (FLT3), receptor tyrosine kinase (KIT), vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor receptor beta. Both in vitro and in vivo studies showed that ETN101 treatment/administration inhibited cancer cell survival and proliferation. In animal models, ETN101 had antitumor activity when administered to animals that did not respond to conventional targeted anticancer agents.
Read the detailed description
The study drug, ETN101, is an mTKI targeting FLT3, VEGFR2, PDGFR-beta, and KIT. Based on its preclinical study results, the study drug was anticipated to have a potent anticancer effect by blocking the signaling pathway of receptor tyrosine kinases. In animal models with subcutaneously transplanted liver cancer cells (HepG2), complete remission (CR) or partial remission (PR) were observed in animals treated with ETN101 at doses of 20~82 mg/kg. In addition, ETN101 82 mg/kg induced CR and PR in animals that had not responded to HCC therapies, sorafenib and lenvatinib. ETN101 10 mg/kg was found to have antitumor efficacy as demonstrated by approximately 30% suppression of tumor growth in comparison with a negative control.
Overall, ETN101 is anticipated to have anticancer activity as a targeted therapy in the treatment of advanced HCC that did not respond to prior therapy or that recurred subsequently, and therefore, is expected to offer a new treatment opportunity for patients with advanced hepatocellular carcinoma (HCC) for whom therapeutic options are limited.
Therefore, this study aims to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of ETN101, and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of ETN101 in patients with HCC who previously had second- or further-line anticancer treatment.
- Being tested
- ETN101
- Keywords
- HCC
- Medical subject headings
- Carcinoma, Hepatocellular, Liver Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ETN101Drug
Oral administration
| Study group | Role | What they receive |
|---|---|---|
| ETN101 | Experimental | ETN101 Receives: Drug: ETN101 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dose-limiting Toxicity (DLT)
DLT will be monitored during Cycle 1 (3 weeks) starting from the start date of intraperitoneal (IP) dosing
Measured: Up to 3 weeks after start of injection
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Mar 2024
- Study start7 Feb 2024
- Primary completion7 Mar 2027 (estimated)
- Study completion7 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Hepatocellular CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Etnova Therapeutics Corp.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Yeonhee Kim, Ph.D, Study director, Etnova Therapeutics
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06326502
- Sponsor's protocol ID
- 22ETN101-2IND001
- Status last verified
- Mar 2024
- First submitted
- 17 Mar 2024
- Last updated
- 27 Mar 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Park HJ, Choi G, Ha S, Kim Y, Choi MJ, Kim M, Islam MK, Chang Y, Kwon TJ, Kim D, Jang E, Kim TH, Chang SJ, Kim YH. MBP-11901 Inhibits Tumor Growth of Hepatocellular Carcinoma through Multitargeted Inhibition of Receptor Tyrosine Kinases. Cancers (Basel). 2022 Apr 14;14(8):1994. doi: 10.3390/cancers14081994.
PubMed 35454900